spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  integrase inhibitor 

 HSMN NewsFeed - 22 Jun 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE(R) drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 19 May 2017
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jan 2014
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 22 Nov 2013
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 7 Mar 2013
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 4 Jun 2010
FDA Approves New Roche Dual-PCR Target HIV-1 Test
Diagnostics FDA HIV/AIDS
 HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 8 Apr 2008
New York Medicaid Program Establishes Coverage for Trofile(TM)
Diagnostics Biopharmaceuticals HIV/AIDS Reimbursement
 HSMN NewsFeed - 28 Feb 2008
Ambrilia Announces the Departure of Dr. Chandra J. Panchal, Executive Vice-President, Business Development, Licensing and IP
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Feb 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 21 Dec 2007
ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 15 Nov 2007
Significant Changes in Store for Growing HIV Market
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 7 Nov 2007
Monogram Obtains Coverage for Trofile(TM) Assay from California ADAP Program
Diagnostics Reimbursement HIV/AIDS
 HSMN NewsFeed - 15 Oct 2007
UPDATE: FDA Approves ISENTRESS(TM) (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 20 Sep 2007
Shareholders Approve Inhibitex Acquisition of FermaVir
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Sep 2007
ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Sep 2007
FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS(TM) (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 27 Jun 2007
FDA Priority Review Granted for ISENTRESS(TM) (raltegravir), Merck's Investigational Integrase Inhibitor for HIV
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 13 Jun 2007
Ambrilia Appoints a New Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2007
Ambrilia Announces the Appointment of Stephen G. Sudovar as Executive Chairman & Interim CEO as Hans Mader is Stepping Down as President & CEO and a $5.4 Million Private Placement
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
Ambrilia Announces European Licensing Partnership with TEVA for its Lead Oncology Product, Octreotide
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Nov 2006
Study Shows Ambrilia's PSP94 Immunoassay to Have Prognostic Value in Prostate Cancer Management
Biopharmaceuticals Diagnostics Oncology Urology
 HSMN NewsFeed - 12 Oct 2006
Ambrilia Biopharma and Merck & Co., Inc. Sign Licensing Agreement Granting Merck Worldwide Rights to Ambrilia's HIV/AIDS Protease Inhibitor Program
Biopharmaceuticals Licensing HIV/AIDS
 HSMN NewsFeed - 5 Oct 2006
New Data Show Unprecedented Undetectable Rates of over 90 Percent in HIV Patients Receiving FUZEON(R) and Investigational Integrase Inhibitor MK-0518
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Oct 2006
Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 8 May 2006
Pfizer to Invest $25 Million in Monogram
Diagnostics Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 9 Feb 2006
Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 9 Jan 2006
Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
integrase inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.